Načítá se...

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study

OBJECTIVES: To evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics. METHODS: This randomised, double-blind, placebo-controlled, multicentre study evaluated adalimumab 40 mg every...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Miyasaka, Nobuyuki, Mukai, Masaya, Matsubara, Tsukasa, Uchida, Shoji, Akama, Hideto, Kupper, Hartmut, Arora, Vipin, Tanaka, Yoshiya
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151516/
https://ncbi.nlm.nih.gov/pubmed/23316080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2012-202433
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!